Prenylated flavonoids as potent phosphodiesterase-4 inhibitors from Morus alba: Isolation, modification, and structure-activity relationship study

被引:42
作者
Guo, Yan-Qiong [1 ]
Tang, Gui-Hua [1 ]
Lou, Lan-Lan [1 ]
Li, Wei [1 ]
Zhang, Bei [1 ]
Liu, Bo [2 ]
Yin, Sheng [1 ]
机构
[1] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China
[2] Guangzhou Univ Chinese Med, Clin Med Coll 2, Guangzhou 510006, Guangdong, Peoples R China
基金
国家高技术研究发展计划(863计划); 中国国家自然科学基金;
关键词
Moms alba; Prenylated flavonoids; Phosphodiesterase-4; inhibitor; CULTIVATED MULBERRY TREE; ROOT BARK; PDE4; INHIBITORS; CONSTITUENTS; DISCOVERY; KUWANON;
D O I
10.1016/j.ejmech.2017.12.057
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The bioassay-guided phytochemical study of a traditional Chinese medicine Moms alba led to the isolation of 18 prenylated flavonoids (1-18), of which (+/-)-cyclomorusin (1/2), a pair of enantiomers, and 14-methoxy-dihydromorusin (3) are the new ones. Subsequent structural modification of the selected components by, methylation, esterification, hydrogenation, and oxidative cyclization led to 14 more derivatives (19-32). The small library was screened for its inhibition against phosphodiesterase-4 (PDE4), which is a drug target for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Among them, nine compounds (1-5, 8, 10, 16, and 17) exhibited remarkable activities with IC50 values ranging from 0.0054 to 0.40 mu M, being more active than the positive control rolipram (IC50 = 0.62 mu M). (+)-Cyclomorusin (1), the most active natural PDE4 inhibitor reported so far, also showed a high selectivity across other PDE members with the selective fold greater than 55. The SAR study revealed that the presence of prenyls at C-3 and/or C-8, 2H-pyran ring D, and the phenolic hydroxyl groups were important to the activity, which was further supported by the recognition mechanism study of the inhibitors with PDE4 by using molecular modeling. (C) 2017 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:758 / 766
页数:9
相关论文
共 34 条
  • [1] Synthesis of Tetracyclic Flavonoids via Palladium-Catalyzed Intramolecular Oxidative Cyclization
    Ayyagari, Narasimham
    Belani, Jitendra D.
    [J]. SYNLETT, 2014, 25 (16) : 2350 - 2354
  • [2] Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use
    Bender, Andrew T.
    Beavo, Joseph A.
    [J]. PHARMACOLOGICAL REVIEWS, 2006, 58 (03) : 488 - 520
  • [3] Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety
    Burgin, Alex B.
    Magnusson, Olafur T.
    Singh, Jasbir
    Witte, Pam
    Staker, Bart L.
    Bjornsson, Jon M.
    Thorsteinsdottir, Margret
    Hrafnsdottir, Sigrun
    Hagen, Timothy
    Kiselyov, Alex S.
    Stewart, Lance J.
    Gurney, Mark E.
    [J]. NATURE BIOTECHNOLOGY, 2010, 28 (01) : 63 - U93
  • [4] Discovery and modelling studies of natural ingredients from Gaultheria yunnanensis (FRANCH.) against phosphodiesterase-4
    Cai, Ying-Hong
    Guo, Yanqiong
    Li, Zhe
    Wu, Deyang
    Li, Xiruo
    Zhang, Heng
    Yang, Junjie
    Lu, Heng
    Sun, Zhaowei
    Luo, Hai-Bin
    Yin, Sheng
    Wu, Yinuo
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 114 : 134 - 140
  • [5] Structural basis for the activity of drugs that inhibit phosphodiesterases
    Card, GL
    England, BP
    Suzuki, Y
    Fong, D
    Powell, B
    Lee, B
    Luu, C
    Tabrizizad, M
    Gillette, S
    Ibrahim, PN
    Artis, DR
    Bollag, G
    Milburn, MV
    Kim, SH
    Schlessinger, J
    Zhang, KYJ
    [J]. STRUCTURE, 2004, 12 (12) : 2233 - 2247
  • [6] Biochemistry and physiology of cyclic nucleotide Phosphocliesterases: Essential components in cyclic nucleotide signaling
    Conti, Marco
    Beavo, Joseph
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 2007, 76 : 481 - 511
  • [7] Fukai T, 1996, HETEROCYCLES, V43, P425
  • [8] Geng Chang'an, 2010, Zhongguo Zhong Yao Za Zhi, V35, P1560
  • [9] Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors
    Giembycz, MA
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2005, 5 (03) : 238 - 244
  • [10] HANO Y, 1983, HETEROCYCLES, V20, P1071